CheckMate914
Por um escritor misterioso
Descrição
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
Et de 3 ! CheckMate 914 : encore un essai négatif en adjuvant pour le rein
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis - Mori - International Journal of Urology - Wiley Online Library
.png)
ASCO热评丨盛锡楠教授：肾癌领域治疗进展-肿瘤瞭望
Enrique Grande on X: 🔘 On @TheLancet - Assessing the efficacy and safety of adjuvant nivolumab + ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914) #immunotherapy #kidneycancer
From neoadjuvant to second-line therapeutic options for RCC patients
Adjuvant Nivolumab/Ipilimumab vs Placebo in Localized Renal Cell Carcinoma - The ASCO Post
Adjuvant Immunotherapy in Resected Renal Cell Carcinoma: Déjà vu or Progress?
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - The Lancet
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
Frontiers Adjuvant therapy for renal cell carcinoma, finally a new standard?
ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial
Adjuvant immunotherapy does not improve DFS in renal cancer
옵디보, '신세포암'에서 희비 교차 < 암/혈액/희귀/소아청소년 < 암/혈액/희귀/소아청소년 < 학술 < 기사본문 - 메디칼업저버
de
por adulto (o preço varia de acordo com o tamanho do grupo)
